A novel treatment that uses a disintegrating matrix for sustained release of medication led to improvement in vision and reduced supplemental treatment in patients with diabetic macular edema, ...

Obesity took center stage on the first day of the 2026 J.P. Morgan Healthcare Conference, with industry frontrunners Eli ...

Regeneron was up 4.7% at $813.38. If the gains hold, the stock will notch its highest close since Nov. 12, 2024, when it ...

Regeneron shares are up 41% in six months as FDA approvals, strong Dupixent profits and oncology gains lift investor confidence.

Even as OpenAI works to harden its Atlas AI browser against cyberattacks, the company admits that prompt injections, a type of attack that manipulates AI agents to follow malicious instructions often ...

Regeneron Pharmaceuticals is poised for a turnaround as Eylea's patent cliff fades and new growth drivers emerge. Dupixent and Libtayo are expected to drive robust revenue and margin expansion, with ...

An announcement from Alvotech ( (ALVO)) is now available. On December 19, 2025, Alvotech reported that it and its U.S. commercial partner Teva Pharmaceuticals have reached a settlement and license ...

Sign up for the Slatest to get the most insightful analysis, criticism, and advice out there, delivered to your inbox daily. Showing the work is the point. Aesthetics ...

(RTTNews) - Alvotech (ALVO) and Teva Pharmaceutical Industries Ltd. (TEVA) have secured a U.S. license entry date for AVT06, the proposed biosimilar to Regeneron's Eylea, setting the stage for a ...

Regeneron has had its hands full this year contending with regulatory setbacks, Amgen's marketed Eylea biosimilar and Roche's hard-charging ophthalmology rival Vabysmo. Next year, the biosimilar ...

Alvotech (ALVO) and Teva Pharmaceuticals (TEVA) have reached a settlement and license agreement with Regeneron Pharmaceuticals (REGN) concerning the launch of AVT06, Alvotech’s proposed biosimilar to ...

According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain ...